Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
OtherArticle

Transcriptome-level interactions between budesonide and formoterol provide insight into the mechanism of action of ICS/LABA combination therapy in asthma

Mahmoud M Mostafa, Christopher F. Rider, N Dulmini Wathugala, Richard Leigh, Mark A. Giembycz and Robert Newton
Molecular Pharmacology December 29, 2020, MOLPHARM-AR-2020-000146; DOI: https://doi.org/10.1124/molpharm.120.000146
Mahmoud M Mostafa
1Physiology & Pharmacology, University of Calgary, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mahmoud M Mostafa
Christopher F. Rider
2Medicine, University of British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christopher F. Rider
N Dulmini Wathugala
1Physiology & Pharmacology, University of Calgary, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Leigh
3Department of Medicine, University of Calgary, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark A. Giembycz
4Physiology and Pharmacology, University of Calgary, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Newton
4Physiology and Pharmacology, University of Calgary, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert Newton
  • For correspondence: rnewton@ucalgary.ca
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

MOLPHARM-AR-2020-000146
DOI 
https://doi.org/10.1124/molpharm.120.000146
PubMed 
33376135

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0026-895X
Online ISSN 
1521-0111
History 
  • Published online December 29, 2020.

Copyright & Usage 
Copyright © 2020 American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Mahmoud M Mostafa1,
  2. Christopher F. Rider2,
  3. N Dulmini Wathugala1,
  4. Richard Leigh3,
  5. Mark A. Giembycz4, and
  6. Robert Newton4,*
  1. 1Physiology & Pharmacology, University of Calgary, Canada
  2. 2Medicine, University of British Columbia, Canada
  3. 3Department of Medicine, University of Calgary, Canada
  4. 4Physiology and Pharmacology, University of Calgary, Canada
  1. ↵* Corresponding Author:
    Robert Newton, Physiology and Pharmacology, University of Calgary, 3330 Hospital Drive NW, Faculty of Medicine, Calgary, T2N 4N1, Canada. E-mail: rnewton{at}ucalgary.ca

Statistics from Altmetric.com

Article usage

Article usage: December 2020 to January 2021

AbstractFullPdf
Dec 2020100013
Jan 2021276090

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 99 (2)
Molecular Pharmacology
Vol. 99, Issue 2
1 Feb 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Transcriptome-level interactions between budesonide and formoterol provide insight into the mechanism of action of ICS/LABA combination therapy in asthma
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherArticle

Transcriptome-level glucocorticoid/LABA interactions

Mahmoud M Mostafa, Christopher F. Rider, N Dulmini Wathugala, Richard Leigh, Mark A. Giembycz and Robert Newton
Molecular Pharmacology December 29, 2020, MOLPHARM-AR-2020-000146; DOI: https://doi.org/10.1124/molpharm.120.000146

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
OtherArticle

Transcriptome-level glucocorticoid/LABA interactions

Mahmoud M Mostafa, Christopher F. Rider, N Dulmini Wathugala, Richard Leigh, Mark A. Giembycz and Robert Newton
Molecular Pharmacology December 29, 2020, MOLPHARM-AR-2020-000146; DOI: https://doi.org/10.1124/molpharm.120.000146
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • P2X7 Positive Modulator Structure-Activity Relationship
  • Predicting Drug Interactions with ENT1 and ENT2
  • GABAAR Molecular Identity in Oligodendrocytes
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics